Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medco and Repligen face the future

Medco and Repligen face the future

Medco Research Inc. shareholders who opposed the terms of the proposed merger with Repligen Corp. got their wish, with the deal foundering last week after the companies couldn't reach a new deal.

The issue now is whether MRE shareholders have traded

Read the full 467 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers